Business
Exclusive option agreement
Exclusive option agreement.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3696V\n Renalytix AI PLC\n 14 April 2021\n \n \n \n \n \n \n \n \n \n \n Renalytix AI plc\n \n \n \n (\"RenalytixAI\" or the \"Company\")\n \n \n \n \n \n \n RenalytixAI and Joslin Diabetes Center Build on Proprietary Kidney Biomarker Portfolio\n \n \n for KidneyIntelX Platform\n \n \n \n \n \n Agreement provides RenalytixAI with exclusive option to access intellectual property\n \n \n surrounding a comprehensive panel of novel biomarkers in kidney disease \n \n \n \n \n \n \n NEW YORK, April 14, 2021\n \n - \n \n \n Renalytix AI plc\n \n \n (LSE: RENX) (NASDAQ: RNLX) announced today that it has entered into an exclusive option agreement with Joslin Diabetes Center for patent filings on certain additional novel biomarkers in kidney disease for development and deployment in the KidneyIntelX in vitro prognostic platform.\n \n \n \n \n \n These novel biomarkers have the potential to provide additional clinical utility for understanding early disease progression and risk of kidney failure, therapeutic response, and the mechanistic pathways of kidney disease beyond the inflammatory and tubular injury markers that are currently captured by KidneyIntelX. RenalytixAI plans to begin evaluating these novel biomarkers in expanded clinical validation studies beginning in the second half of 2021. \n \n \n \n \n \n \"These proprietary blood biomarkers have the potential to significantly expand the utility of the KidneyIntelX platform, particularly in understanding how to efficiently enroll and characterize appropriate participants in new drug validation trials. We believe they could also contribute to a better understanding of patient response to approved drug therapies,\n \" said Fergus Fleming, Chief Technology Officer, RenalytixAI. \"We look forward to working with Joslin and other research and pharma collaborators to build a platform to advance our understanding of underlying causal pathways of kidney disease, and bring precision medicine solutions to clinical practice.\" \n \n \n \n \n \n In 2018, RenalytixAI secured an exclusive license from Joslin Diabetes Center to intellectual property relating to sTNFR1 and sTNFR2, both of which have been extensively validated as highly prognostic biomarkers in multiple settings an...